management can offer better outcomes, with surveillance for at-risk relatives and nephron sparing surgery through earlier intervention.
Introduction
An apparently balanced t(2;3)(q37.3;q13.2) translocation appears to segregate with renal cell carcinoma (RCC) in a previously reported family [1] . The breakpoint was identified incidentally by virtue of being in the regions of highest genetic linkage during a genome scan for vesicoureteric reflux [2] . The breakpoint on chromosome 2 is between Abstract An apparently balanced t(2;3)(q37.3;q13.2) translocation that appears to segregate with renal cell carcinoma (RCC) has indicated potential areas to search for the elusive genetic basis of clear cell RCC. We applied Hi-Plex targeted sequencing to analyse germline DNA from 479 individuals affected with clear cell RCC for this breakpoint translocation and genetic variants in neighbouring genes on chromosome 2, ACKR3 and COPS8. While only synonymous variants were found in COPS8, one of the missense variants in ACKR3:c. 892C>T , observed in 4/479 individuals screened (0.8%), was predicted likely to damage ACKR3 function. Identification of causal genes for RCC has potential clinical utility, where risk assessment and risk Maryam Mahmoodi and Tu Nguyen-Dumont contributed equally to this work.
Atypical Chemokine Receptor 3 (ACKR3), previously known as CXC Chemokine Receptor 7 (CXCR7) and COP9 Signalosome Subunit 8 (COPS8). ACKR3/CRCX7 is known to be involved in kidney development and is overexpressed in ~50% of RCC [3, 4] . Expression measured by immunohistochemistry in the tumours of the family members carrying the translocation has been found not to be consistent (unpublished data). The breakpoint on chromosome 3 bisects CD96, which has been implicated in C (Opitz trigonocephaly) syndrome [5] but not in RCC. On the basis of these findings, it is plausible that genes neighbouring the t(2;3) translocation may have a role in the genesis of RCC. We, therefore, examined ACKR3 and COPS8 and tested for t(2;3)(q37.1;q13.2) in the germline DNA obtained from participants from the Consortium for the Investigation of Renal Malignancies (CONFIRM).
Materials and methods

Specimens
CONFIRM utilizes a case-control design to investigate the epidemiological and genetic risk factors for renal cell carcinoma. Cases were recruited via the Victorian and Queensland Cancer Registries and familial cancer centers across Australia. Eligible participants are those diagnosed at <75 years of age. Participation involves completing epidemiological questionnaires about lifestyle, medical history, diet and family history of cancer and providing a blood sample.
DNA from 479 participants with a renal malignancy were extracted using the Roche MagNA Pure 96 Blood protocol system and quantitated using the Qubit dsDNA Assay system (ThermoScientific, Waltham, MA, USA), according to the manufacturer's instructions.
Hi-Plex mutation screening
Twenty eight gene-specific primer pairs (GSP) were designed to target protein-coding region co-ordinates for ACKR3 (NM_020311) and COPS8 (NM_006710). One additional primer pair (5′-3′ DNA sequences CCT CTG AAT GAG AGA TCC TC and GAC TAA TAT TCA GTA AGA CCAGA, respectively) spans the chr2:237,594,844-237,594,846 and chr3:111,305,167-111,305,169 (hg19) breakpoint genomic rearrangement. These were designed so that the breakpoint was significantly offset from the centre of the amplicon to facilitate subsequent mapping to the hg19 human reference genome-build. The sequences of other GSPs are available on request. Their general structures were similar to those described in earlier reports [6] . Since the present work, we have developed an improved primer design algorithm that minimises primer-dimer off-target effects, yields more uniform coverage across amplicons and allows more stringent reaction conditions for improved assay performance [7] . The non-GSP library insert regions were designed in a narrow size range around 100 bp to facilitate complete overlap of read-pairs-based analyses [8, 9] . All primers were synthesised by Integrated DNA Technologies (Coralville, IA, USA) and purified to standard desalting grade. 'F8_bridge' and 'R5_bridge' abridged adapter universal primers have 5′-3′-oriented DNA sequences of CTC TCT ATG GGC AGTC and CTG CGT GTC TCC GAC, respectively [10] . Full-length, dualindexing adapter primer sequences have been reported previously in [11] . We used additional Illumina Nextera indices for dual indexing to enable 192 pooled specimen libraries to be analysed on a single sequencing run.
Individual Hi-Plex PCR reactions were conducted in wells of a skirted PCR plate, each in a final volume of 25 μL with 1xPhusion ® HF PCR buffer (ThermoScientific), one unit of Phusion Hot Start II High-Fidelity DNA Polymerase (ThermoScientific), 400 μM dNTPs (Bioline, London, UK), 0.125 M gene-specific primer pool aggregate (individual gene-specific primer concentrations vary and are described in [11] ), 1 μM 'Bridge' primers [12] , 2.5mM MgCl 2 (ThermoScientific) and 25 ng input genomic DNA. The following steps were then applied: 98 °C for 1 min, 25 cycles of (98 °C for 30 s, 50 °C for 1 min, 55 °C for 1 min, 60 °C for 1 min, 65 °C for 1 min, 70 °C for 1 min), addition of 1 μM dual-indexed hybrid adapter primers, then a further three cycles of (98 °C for 30 s, 68 °C for 1 min, 70 °C for 1 min), followed by incubation at 68 °C for 20 min. Pooled library size-selection, quantification and sequencing were performed as detailed in [12] . 5 µL of each reaction were pooled before subjecting the resulting barcoded library (including the 96 sub-libraries) to electrophoresis on a 1.5% HR-agarose gel (ThermoScientific). Size selection, gel extraction and purification were performed as described previously [12] .
The library was then sequenced on a MiSeq instrument, using the 300 bp MiSeq Reagent kit v2 (Illumina). Prior to performing the run, 3.4 µL of 100 µM sequencing primers were added to the respective read1, read2 and i7 primer reservoirs in the reagent cartridge as described in [11] . Sequencing data were mapped to the entire human genome (hg19) using bowtie2-2.1.0 [13] applying default parameters except for-trim5 20-trim3 20. Bedtools v2.16.1 [14] was used to compute on-target coverage. ROVER variant caller [8] was applied using a variant proportion threshold of 0.25 and minimum required variant depth of ten read-pairs. We also filtered mapping artefacts from the data according to methods described in [15] . Genetic variants were annotated using the web version of ANNOVAR (accessed on 29th November 2016) [16] . Predictions were obtained from the following programs, using their default settings: SIFT [17] , PolyPhen-2 [18] , Mutation Taster [19] and CADD [20] . For breakpoint analysis, the parameterstrim5 0-trim3 60 were applied with bowtie2-2.1.0. An inhouse script was used to count reads mapping to the chromosome 2 region of the breakpoint rearrangement.
The threshold for successful sequencing was set to a minimum 26/28 amplicons covered by ≥10 read pairs. Variant confirmation was performed by Sanger Sequencing using BigDye Terminator v3.1 (Life Technologies), according to the manufacturer's instructions.
Results
We screened the coding region and proximal intron-exon junctions of ACKR3 and COPS8 in 479 subjects by targeted-MPS, using Hi-Plex. The target regions consisted of a total of 28 Hi-Plex amplicons. Successful sequencing was achieved for 472/479 specimens (98.5%). The average on target rate was 98.98% across the 28 amplicons. The median coverage was 1258 reads.
The (Table 1) .
Of the five missense variants, ACKR3:c.892C>T, was predicted to be probably damaging to protein function by PolyPhen-2, Mutation Taster and CADD. SIFT did not provide a prediction because of low sequence diversity in the protein multiple sequence alignment at that position. This variant was observed in 4/479 individuals screened (0.83%) and is present in the Exome Variant Server with a carrier frequency of 0.47% in the non-Finnish European population [21] . In these four affected participants, age at diagnosis ranged from 40 to 57 years and two came from families with multiple cancers. More information on these participants is presented in Table 2 . There was no other missense variant for which the prediction tools were in agreement. ACKR3:c.1007C>T was not annotated by SIFT for the same reasons as described above and Mutation Taster predicted this variant as "probably deleterious". However, 
it was not ranked as high as ACKR3:c.892C>T by PolyPhen-2 ("possibly damaging", whereas ACKR3:c.892C>T was classified as "probably damaging"-the most deleterious class for PolyPhen-2). CADD phred-scaled score for ACKR3:c.1007C>T is below 20, which means this variant is not predicted to be amongst the top 1% of deleterious variants in the human genome (the CADD score for Table 3) .
The Hi-Plex assay also included primers designed to detect a breakpoint genomic rearrangement. The assay detected the breakpoint mutation in two known carriers used as positive controls in the assay. However no new carriers of this rearrangement were identified in this screening.
Discussion
Approximately 3-5% of renal cancer is familial [22] . RCC with specific histologies can be attributed to genetic syndrome, such as the chromophobe RCC often observed with pneumothorax and skin lesions and associated with mutations in FLCN and Birt-Hogg-Dube syndrome [23] and the papillary type 2 RCC associated with cutaneous leiomyoma in Hereditary Leiomyomatosis RCC syndrome caused by mutations in FH [24] . While the genetic basis of syndromic renal cancer is well known, susceptibility genes for clear cell RCC are yet to be described. In von Hippel-Lindau syndrome, clear cell RCC unusually occurs alone; heterozygous mutations in the VHL gene cause a highly penetrant clinical constellation, including haemangioblastoma, phaeochromocytoma and clear cell RCC [25] .
It is plausible that the breakpoints of the previously reported apparently balanced t(2;3)(q37.3;q13.2) translocation incorporate a potential clear cell RCC susceptibility gene, especially since there were three individuals affected with RCC in the family who also carried this translocation.
ACKR3 acts as a receptor for the inflammatory chemokine CXCL11 and for the constitutive chemokine CXCL12, which is involved in tumor cell survival, migration, and tumour development. Activation of ACKR3 leads to arrestin recruitment as a signalling response. Studies of mouse models have shown that ACKR3 facilitates angiogenesis and that tumour growth is inhibited when ACKR3 is blocked [26] . Thus, it has been suggested to participate in tumour angiogenesis and Maishi et al. have reported that tumour blood vessels highly express ACKR3 in RCC [4] . Five missense variants were identified in ACKR3 of which one, ACKR3:c.892C>T, was predicted probably damaging to protein function by three of four in-silico prediction tools. This missense substitution falls into the highly conserved seven transmembrane receptor domain (7tm_1). Missense variants are challenging to interpret and further studies will be required to investigate the functional impact of ACKR3:c.892C>T on protein function if future large scale screening studies confirm the association of ACKR3 in predisposition to RCC. A possible mechanism by which missense variants in ACKR3 might affect protein function is by introducing an amino acid substitution that would increase the stability of AKCR3 and thus the relative cellular abundance. As ACKR3 is a receptor, a missense substitution such as ACKR3:c.892C>T might render the protein constitutively active, i.e. active without the requirement of binding from a ligand. The possible consequences of such a gain-of-function mutation would be consistent with previously reported overexpression of ACKR3 in RCC cases [3, 4] . Screening of COPS8 identified three genetic variants, all of which were synonymous providing no evidence COPS8 playing a role in RCC predisposition.
The Hi-Plex assay also included primers designed to detect a breakpoint genomic rearrangement. We were able to detect the breakpoint mutation in two known carriers used as positive controls in the assay, showing this to be an effective methodology.
Identification of susceptibility genes for RCC has potential clinical utility, as improved risk assessment and risk management can offer better outcomes, particularly with earlier nephron sparing surgery. Studies to elucidate such genes are continuing.
